Presenters
Endocrinologist
Prof. Alexander Tan, MD
Course Details
The aim of this webinar is to provide updates on how Linagliptin has brought improvements in diabetes care over the last 10 years. It will discuss the clinical trials of linagliptin – its efficacy, cardiovascular and renal safety and convenience across a broad range of T2D patients, and how it helps make the management of a complex disease more simple
Estimated time of Completion: 45 mins
CPD Points: 0.75 Point
PRC Program No: PROG-2022-44091
A Decade of Simplicity in T2D Management: Why it Matters? Course Outline
- Overview of DPP4 Inhibitors
- Linagliptin has proven efficacy and safety in a broad range of patient profiles
- Overall Safety of Linagliptin as seen in CARMELINA® and CAROLINA®
- Summary of clinical evidence from CVOTs in the DPP4 Inhibitor Class
- Linagliptin + Metformin Benefits
- Course Evaluation
PC-PH-104469 / December 2022